HARARE, (The Southern African Times) – The Zimbabwe Investment and Development Agency (Zida) is developing a medicinal cannabis sector-based strategy to promote investments into the country. To date, 54 local and foreign investors have been licensed.
The Ministry of Lands, Agriculture, Fisheries, Water, Climate and Rural Resettlement is working closely with Zida and Medicines Control Authority of Zimbabwe (MCAZ) in ensuring that the quality of seeds imported meet the regulatory requirements while the Tobacco Research Board (TRB) is currently testing and propagating 15 varieties of cannabis to monitor their suitability and potency.
Zida, through the One Stop Shop Investment Services Centre (OSISC), is accepting applications into this sector where investors are allowed to own 100% of their investments. The legislation allows for cultivation in greenhouses only and farming can be done on private land with an ideal security system including real time smart technology.
The security services are key in enforcement of monitoring and evaluation and investors are allowed to use private security and should meet outlined minimal standards of security. Other countries that are offering the same license in the region include Zambia, Rwanda, Malawi and Rwanda; and Zimbabwe.
Following concerns raised about the investment climate in Zimbabwe, Zida, through its act is giving guarantees to investors supported by the Investment Stability Agreement (ISA) which clearly outlines guarantees that include property rights against change in law and expropriation.
Every investor is required to sign the ISA which ZIDA signs on behalf of government. In coming up with the ISA, the Attorney-General’s Office, Cannabis Industry Association of Zimbabwe (CIAZ) and relevant stakeholders were consulted.
Incentives, Economic gain
The government is offering monetary and fiscal incentives administered by Zida, Ministry of Finance and Economic Development in liaison with the Reserve Bank of Zimbabwe. Investors can retain their foreign currency for up to six months from receipt of their export proceeds.
To avoid the cost of doing business, and the fact that medicinal cannabis is mostly an export product, therefore investors are given special incentives and in return, Zimbabwe has approved a medicinal cannabis levy.
The variation of the levy is 20% on the raw cannabis, 15% on semi-processed cannabis and 10% on fully-processed cannabis. The proceeds from this levy shall be used to establish the Green Industry Fund. All collections of taxes shall be performed by the Zimbabwe Revenue Authority (Zimra).
Medical, scientific research
Cannabinoids are chemicals found in cannabis. Cannabinoids are naturally occuring, biologically active chemical constituents of hemp and cannabis such as cannabidiol (CBD) and delta 9-tetrahydrocannabinol (THC). CBD has anti-psychoactive effects whereas THC has psychotic ingredients.
THC is the chemical that causes the “high” that goes along with cannabis consumption. One cannabis plant produces between 80 and 100 cannabinoids and about 300 non-cannabinoid chemicals. THC acts on specific receptors in the brain known as cannabinoid or CB1 receptors. THC has analgesic, anti-inflammatory and antioxidant properties.
CBD is majorly used for medical purposes due to its non-psychotic effect and low levels of toxicity, whereas THC is utilised to reduce the side-effects of AIDS and cancer treatment
Studies done so far have shown that medicinal cannabis has been used successfully in managing chronic pain, epilepsy, insomnia, nausea, anxiety, Crohns’ disease, spasticity, depression, arthritis, endometriosis, cancer, multiple sclerosis as well as a muscle relaxant. CBD-dominant strains called Charlotte’s web have been identified to treat childhood epilepsy called Dravet Syndrome.
Cannabis is safer and has less severe side effects in comparison to other treatment options. It also finds usage along with other treatments either to enhance their efficacy or to combat adverse side effects.
For instance, it is very effective in reducing nausea and increasing appetite among chemotherapy patients. Similarly, it is also used in combination with traditional opioid painkillers, which enables patients to reduce the dosage and frequency of opioids significantly and imparts greater pain relief.
Medicinal cannabis is safer than opiates such as Aleve and medicinal cannabis can take the place of some NSAIDS if people can’t take them due to problems with their kidneys/ ulcers. Medical markets are experiencing growth as more consumers turn to cannabis for its therapeutic applications.
Whither medicinal cannabis?
Over the years, many people have consumed cannabis (marijuana) illegally all over the world. It was used medicinally in ancient Indian, Chinese, Egyptian and Islamic cultures. Developments in medical advancements have seen increased use for medicinal purposes.
Owing to its therapeutic benefits, cannabis has been approved for medical use in numerous countries, with varying degrees of legal restrictions.
However, countries around the world are amending their regulations around cannabis, moving from prohibiting to controlling and taxing these products. Some of these countries include Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Germany, Italy, Mexico, Spain, the United Kingdom, the United States and Uruguay.
The government of Zimbabwe joined the jamboree by crafting into law, the Statutory Instrument (SI) 62 of 2018 (Dangerous Drugs Act), which legalises cultivation and processing of cannabis for medicinal and scientific research (SI 62/2018).
The medicinal cannabis sector is projected to grow to $68 billion by 2027, and Zimbabwe is pressing to get a share of this market. The big players in this space include Canopy Growth Corporation, GW Pharmaceuticals Plc, Aurora Cannabis Inc, Aphria Inc, MedReleaf Corporation, Insys Therapeutics Inc, CanniMed Therapeutics Inc, Cara Therapeutics Inc and United Cannabis Corporation.
Zida was set up to facilitate, promote and protect investments into Zimbabwe. Zida is handling investments in all sectors including medicinal cannabis. The regulation of the sector is carried out by MCAZ under the Ministry of Health and Child Care. The Health ministry is responsible for the administration of the SI 62 of 2018, which governs the sector.